|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15301531153215331534153515361537153815391540...15771578» |
- cisplatin / Generic mfg.
Trial initiation date, Metastases: Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis (clinicaltrials.gov) - Sep 24, 2015
P1, N=11, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Initiation date: May 2006 --> Dec 2007
- pegylated liposomal doxorubicin / Generic mfg.
New trial: HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors (clinicaltrials.gov) - Sep 23, 2015
P=N/A, N=0, Withheld, Sponsor: [Redacted]
- Enrollment open, Surgery: Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery (clinicaltrials.gov) - Sep 21, 2015
P1, N=21, Recruiting, Sponsor: Blaze Bioscience Inc.
Initiation date: May 2006 --> Dec 2007 Not yet recruiting --> Recruiting
- New trial: Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues (SkinAge). (clinicaltrials.gov) - Sep 18, 2015
P=N/A, N=60, Recruiting, Sponsor: Centre Oscar Lambret
- |||||| Lartruvo (olaratumab) / Eli Lilly
Enrollment open, Metastases: ANNOUNCE: A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 17, 2015
P3, N=460, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- alisertib (MLN8237) / Puma
Enrollment change, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Sep 16, 2015
P2, N=59, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=135 --> 59 | Trial primary completion date: Feb 2016 --> Aug 2015
- Trial completion, Trial primary completion date: NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) (clinicaltrials.gov) - Sep 16, 2015
P1/2, N=15, Completed, Sponsor: University Hospital, Basel, Switzerland
N=135 --> 59 | Trial primary completion date: Feb 2016 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Mar 2011
- | Tevimbra (tislelizumab-jsgr) / BeiGene
Phase classification, Metastases: BGB-A317_Study_001: Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors (clinicaltrials.gov) - Sep 16, 2015
P1a/1b, N=64, Recruiting, Sponsor: BeiGene
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Mar 2011 Phase classification: P1 --> P1a/1b
- || Fragmin (dalteparin sodium) / Pfizer, Eisai
Trial primary completion date: Dalteparin in Preventing DVT in Participants With Cancer (clinicaltrials.gov) - Sep 14, 2015
P=N/A, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P1 --> P1a/1b Trial primary completion date: Jul 2016 --> Jul 2017
- New trial: Genetic and Telomere Characteristics of High of Grade Soft Tissue Sarcomas (clinicaltrials.gov) - Sep 14, 2015
P=N/A, N=100, Recruiting, Sponsor: University Hospitals, Leicester
- | linsitinib (ASP7487) / Sling Therap
New P2 trial, Metastases: LINES: Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma (clinicaltrials.gov) - Sep 14, 2015
P2, N=40, Recruiting, Sponsor: University of Oxford
- New trial: Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients (clinicaltrials.gov) - Sep 14, 2015
P=N/A, N=100, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Enrollment change: Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI (clinicaltrials.gov) - Sep 10, 2015
P=N/A, N=50, Recruiting, Sponsor: Stanford University
Trial primary completion date: Jul 2016 --> Jul 2017 N=40 --> 50
- rhIL-15 / National Cancer Institute
Trial completion, Enrollment change, Trial primary completion date, Metastases: NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors (clinicaltrials.gov) - Sep 10, 2015
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
N=40 --> 50 Recruiting --> Completed | N=51 --> 15 | Trial primary completion date: Feb 2017 --> Sep 2015
- Avastin (bevacizumab) / Roche, carotuximab IV (ENV-105) / Kairos Pharma
Enrollment closed: Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Sep 9, 2015
P2, N=128, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=51 --> 15 | Trial primary completion date: Feb 2017 --> Sep 2015 Recruiting --> Active, not recruiting
- New trial, HEOR, Cost effectiveness: MARGIC: Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment (clinicaltrials.gov) - Sep 9, 2015
P=N/A, N=90, Not yet recruiting, Sponsor: Nantes University Hospital
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Sep 8, 2015
P2, N=50, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2015 --> Jul 2017
- | Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Trial primary completion date, Metastases: Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma (clinicaltrials.gov) - Sep 8, 2015
P2, N=47, Active, not recruiting, Sponsor: Vector Oncology
Trial primary completion date: Jul 2015 --> Jul 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> May 2016
- Crixivan (indinavir sulfate) / Merck (MSD)
Trial primary completion date, Combination therapy, IO biomarker, Metastases: Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma (clinicaltrials.gov) - Sep 3, 2015
P2, N=25, Active, not recruiting, Sponsor: Barbara Ensoli, MD
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> May 2016 Trial primary completion date: Jun 2015 --> Oct 2015
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker, Surgery, Metastases: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 3, 2015
P1, N=42, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- New trial, HEOR: Outcomes in Lower Extremity Soft Tissue Sarcoma Patients After Limb Salvage (clinicaltrials.gov) - Aug 31, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: Helsinki University Central Hospital
- ThermoDox (lyso-thermosensitive liposomal doxorubicin) / Imunon
New P1 trial: A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors (clinicaltrials.gov) - Aug 31, 2015
P1, N=34, Not yet recruiting, Sponsor: AeRang Kim
- || Trial primary completion date: FORTO: A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX (clinicaltrials.gov) - Aug 26, 2015
P=N/A, N=150, Recruiting, Sponsor: Isofol Medical AB
Not yet recruiting --> Recruiting Trial primary completion date: May 2015 --> Nov 2015
- Enrollment change, Trial withdrawal, Trial primary completion date: Proton Radiation Therapy for Spinal Tumors (clinicaltrials.gov) - Aug 25, 2015
P2, N=0, Withdrawn, Sponsor: University of Florida
Trial primary completion date: May 2015 --> Nov 2015 N=34 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: May 2025 --> Aug 2015
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment status: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (clinicaltrials.gov) - Aug 25, 2015
P2b, N=58, Recruiting, Sponsor: Medical Research Council
N=34 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: May 2025 --> Aug 2015 Enrolling by invitation --> Recruiting
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Trial initiation date, Combination therapy, Metastases: A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas (clinicaltrials.gov) - Aug 25, 2015
P2, N=60, Recruiting, Sponsor: Massachusetts General Hospital
Enrolling by invitation --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Aug 2015
- ||| Enrollment closed, Metastases: Study of 124I-NM404 in Advanced Solid Malignancies (clinicaltrials.gov) - Aug 24, 2015
P1/2, N=108, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Aug 2015 Recruiting --> Active, not recruiting
- zoledronic acid / Generic mfg.
Enrollment change, Trial primary completion date: Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (clinicaltrials.gov) - Aug 22, 2015
P1, N=21, Not yet recruiting, Sponsor: University of Wisconsin, Madison
Recruiting --> Active, not recruiting N=36 --> 21 | Trial primary completion date: Jan 2018 --> May 2018
- Trial primary completion date: DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 22, 2015
P1/2, N=30, Recruiting, Sponsor: Affiliated Hospital to Academy of Military Medical Sciences
N=36 --> 21 | Trial primary completion date: Jan 2018 --> May 2018 Trial primary completion date: Jun 2015 --> Dec 2015
- Trial primary completion date, Surgery: Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic Surgery (clinicaltrials.gov) - Aug 21, 2015
P2, N=100, Recruiting, Sponsor: First Affiliated Hospital, Sun Yat-Sen University
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: May 2015 --> Oct 2015
- Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Aug 21, 2015
P1, N=18, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2015 --> Oct 2015 Trial primary completion date: Oct 2015 --> Apr 2016
- ID-LV305 / Merck (MSD)
Trial primary completion date, Metastases: Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 (clinicaltrials.gov) - Aug 21, 2015
P1, N=42, Recruiting, Sponsor: Immune Design
Trial primary completion date: Oct 2015 --> Apr 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- Ogsiveo (nirogacestat) / SpringWorks Therap
Trial primary completion date: Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis (clinicaltrials.gov) - Aug 21, 2015
P2, N=17, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Oct 2015
- melphalan / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Aug 21, 2015
P1, N=10, Recruiting, Sponsor: University of Louisville
Trial primary completion date: Dec 2016 --> Oct 2015 Trial primary completion date: Oct 2015 --> Oct 2016
- CMB305 / Merck (MSD)
Enrollment change, Trial primary completion date, Metastases: Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (clinicaltrials.gov) - Aug 21, 2015
P1, N=45, Recruiting, Sponsor: Immune Design
Trial primary completion date: Oct 2015 --> Oct 2016 N=33 --> 45 | Trial primary completion date: Aug 2017 --> Dec 2017
- Enrollment change, IO biomarker, Surgery, Metastases: TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 21, 2015
P1, N=18, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=33 --> 45 | Trial primary completion date: Aug 2017 --> Dec 2017 N=12 --> 18
- Enrollment open: Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=60, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
N=12 --> 18 Not yet recruiting --> Recruiting
- ||| Sutent (sunitinib) / Pfizer
Trial completion, Phase classification, Enrollment change, Trial primary completion date, Stroma: Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=480, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | N=200 --> 480 | Trial primary completion date: Jul 2016 --> May 2013
- || CC-115 / BMS
Phase classification, Enrollment change, Trial initiation date, Metastases: Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. (clinicaltrials.gov) - Aug 20, 2015
P1a/1b, N=75, Active, not recruiting, Sponsor: Celgene Corporation
Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | N=200 --> 480 | Trial primary completion date: Jul 2016 --> May 2013 Phase classification: P1 --> P1a/1b | N=144 --> 75 | Initiation date: Apr 2011 --> Oct 2011
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Tumor mutational burden, PD(L)-1 Biomarker, Surgery, Metastases: Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 19, 2015
P2, N=84, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P1 --> P1a/1b | N=144 --> 75 | Initiation date: Apr 2011 --> Oct 2011 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Ipilimumab and Imatinib Mesylate in Advanced Cancer (clinicaltrials.gov) - Aug 19, 2015
P1, N=96, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- New trial, Surgery: Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=12, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- decitabine / Generic mfg.
Trial primary completion date: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Aug 19, 2015
P1, N=15, Recruiting, Sponsor: University of Louisville
Active, not recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Aug 2016
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Trial primary completion date, Surgery: GEIS: Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults (clinicaltrials.gov) - Aug 18, 2015
P2, N=43, Active, not recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Trial primary completion date: Aug 2015 --> Aug 2016 Completed --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2016
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) (clinicaltrials.gov) - Aug 17, 2015
P1, N=11, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2016 No longer recruiting --> Completed
- Trial primary completion date, Metastases: Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer (clinicaltrials.gov) - Aug 17, 2015
P1, N=63, Active, not recruiting, Sponsor: University of Chicago
No longer recruiting --> Completed Trial primary completion date: Jun 2010 --> Jun 2016
- || Vigil (gemogenovatucel-T) / Gradalis
Enrollment closed, Tumor cell, Metastases: Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer (clinicaltrials.gov) - Aug 17, 2015
P1, N=100, Active, not recruiting, Sponsor: Gradalis, Inc.
Trial primary completion date: Jun 2010 --> Jun 2016 Recruiting --> Active, not recruiting
- Trial primary completion date: Genomic Structural Variation in Cancer Susceptibility (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=1250, Enrolling by invitation, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2015 --> Oct 2016
- | lenalidomide / Generic mfg.
New P2 trial: A Study of Lenalidomide for Adult Histiocyte Disorders (clinicaltrials.gov) - Aug 14, 2015
P2, N=12, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- Avastin (bevacizumab) / Roche
Trial termination, Surgery: Radiosurgery Plus Bevacizumab in Glioblastoma (clinicaltrials.gov) - Aug 14, 2015
P1/2, N=9, Terminated, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Oct 2015 --> Oct 2016 Active, not recruiting --> Terminated; Slow Accrual